Year None2024202320222021202020192018201720162014 Jun 05, 2024 | Annexon Announces Pricing of $125 Million Underwritten Public Offering Jun 04, 2024 | Annexon Announces Proposed Public Offering of Common Stock Jun 04, 2024 | Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome Jun 03, 2024 | Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data May 16, 2024 | Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) May 13, 2024 | Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones May 09, 2024 | Annexon Biosciences to Present at the Bank of America Health Care Conference May 07, 2024 | Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting May 01, 2024 | Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting Apr 16, 2024 | Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Next page next › Last page last » Displaying 11 - 20 of 27 News Resources RSS Feeds Email Alerts